Neural mechanisms underlying the onset and maintenance of epileptic seizures involve alterations in inhibitory and/or excitatory neurotransmitter pathways. Thus, the prospecting of novel molecules from natural products that target both inhibition and excitation systems has deserved interest in the rational design of new anticonvulsants. We isolated the alkaloids (+)-erythravine and (+)-11-α-hydroxyerythravine from the flowers of Erythrina mulungu and evaluated the action of these compounds against chemically induced seizures in rats. Our results showed that the administration of different doses of (+)-erythravine inhibited seizures evoked by bicuculline, pentylenetetrazole, and kainic acid at maximum of 80, 100, and 100%, respectively, whereas different doses of (+)-11-α-hydroxy-erythravine inhibited seizures at a maximum of 100% when induced by bicuculline, NMDA, and kainic acid, and, to a lesser extent, PTZ (60%). The analysis of mean latency to seizure onset of nonprotected animals, for specific doses of alkaloids, showed that (+)-erythravine increased latencies to seizures induced by bicuculline. Although (+)-erythravine exhibited very weak anticonvulsant action against seizures induced by NMDA, this alkaloid increased the latency in this assay. The increase in latency to onset of seizures promoted by (+)-11-α-hydroxy-erythravine reached a maximum of threefold in the bicuculline test. All animals were protected against death when treated with different doses of (+)-11-α-hydroxy-erythravine in the tests using the four chemical convulsants. Identical results were obtained when using (+)-erythravine in the tests of bicuculline, NMDA, and PTZ, and, to a lesser extent, kainic acid. Therefore, these data validate the anticonvulsant properties of the tested alkaloids, which is of relevance in consideration of the ethnopharmacological/biotechnological potential of E. mulungu.
Introduction
Epilepsy is a set of chronic disorders that modify brain function and are associated with the occurrence of sudden and unexpected seizures of convulsive or nonconvulsive nature. Most epileptic syndromes have particular neurophysiological and clinical characteristics, the seizures being the result of abnormal, hyperactive, or hypersynchronous neuronal discharges [1] . Moreover, neuronal mechanisms underlying the onset and maintenance of the epilepsies involve marked alterations in the balance between excitatory and inhibitory neurotransmission pathways in the central nervous system (CNS) [1, 2] .
In most cases, treatment of the epilepsies consists of maintaining the patient seizure free with anticonvulsant drugs. These drugs suppress synaptic hyperactivation by acting on ion channels, metabolic enzymes, or neurotransmitter transporters or receptors, the latter involving chiefly GABA and/or glutamate [3] . Despite the considerable number of antiepileptic drugs, there is a need for novel medicines, as not all patients with epilepsy respond satisfactorily to the usual treatments, and also because these drugs have side effects such as cognitive impairment, sedation, teratogenesis, and hirsutism with chronic use [4] [5] [6] [7] . In light of these facts, the search for novel anticonvulsant compounds of different chemical nature and the modification of the structure of traditional drugs may lead to the generation of more effective and better tolerated drugs, as well as to a better understanding of the mechanisms through which the brain becomes epileptic [6] .
Erythrina mulungu (Sin. Corallodendron mulungu (Martius) Kuntze, Erythrina flammea Herzog, Erythrina mulungu Mart. ex Benth.) is a deciduous tree found mainly in Brazilian cerrados and other tropical regions [8, 9] . The flowers, fruits, seeds, and bark are frequently used in folk medicine because of their effects on the CNS; for example, anticonvulsant, antidepressant, analgesic, sedative, and hypnotic effects are some of those actions validated by different experimental models [8, [10] [11] [12] . Indeed, experiments have pointed to the effective anxiolytic activity of E. mulungu hydroalcoholic extract [13] [14] [15] and also to its anticonvulsant effects against seizures induced by different chemoconvulsants [16] . Chromatographic purification of the E. mulungu hydroalcoholic extract led to the identification of some alkaloids with effective anxiolytic activity, among which are (+)-erythravine and (+)-11α-hydroxy-erythravine [17, 18] .
As anxiolytics may also function as antiepileptic drugs and based on the popular use of E. mulungu as well as on previous reports pointing to the anticonvulsant properties of the hydroalchoolic extract of this plant, the aim of the present work was to investigate the anticonvulsant properties of (+)-erythravine and (+)-11α-hydroxy-erythravine alkaloids, analyzing their effectiveness in the blockade of seizures induced in rats by two GABAergic antagonists, bicuculline and pentylenetetrazole (PTZ), and two glutamatergic agonists, NMDA and kainic acid.
Material and Methods

Chemicals
Most of the chemical agents, reagents, and solvents used in this study were purchased from Sigma-Aldrich (USA) or Merck (USA), unless otherwise specified. Diazepam, ketamine, and xylazine, acquired from Germed (Brazil), Agener União (Brazil), and Hertape Callier (Brazil), respectively, were injected in a final volume of 0.3 mL (intraperitoneally). All reagents were of analytical grade. (+)-Erythravine and (+)-11-α-hydroxy-erythravine were diluted in saline solution before bioassay and administered in a total volume of 1 μL (intracerebroventricularly).
Animals
Male Wistar rats (200-250 g) were acquired from animal housing at the University of São Paulo in Ribeirão Preto-SP, Brazil. Animals were maintained under controlled conditions of light (12-hour darklight cycle, lights on at 7:00 AM), temperature (25°C), and humidity (55%). This work was approved by the Ethics Committee for Experimental Animals at UNAERP (006/08). Experimental procedures were performed according to the rules in the Handbook of Animal Experimentation and Care from the Brazilian Society of Neurosciences and Behavior. Furthermore, all efforts were made to avoid unnecessary stress and pain for the animals. Flowers from E. mulungu (5.0 kg) were collected in Rifaina, São Paulo, Brazil (latitude 20°07'41.7'', longitude 47°281'54.5'', 1037-GPS). Flowered branches were herborized according to the guide of the Medicinal Plants Herbarium in UNAERP and labeled with a voucher number (HPMU-1330).
Purification procedures followed those described by Flausino and colleagues [17] . Briefly, fresh flowers were macerated in a 50 L solution of ethanol:water (7:3, v/v). After 15 days, the extract was filtered and the solvent submitted to rotary evaporation. The aqueous extract was lyophilized, resulting in 86.905 g of dry extract, which was dissolved in a solution of acetic acid:water (10%, v/v) and submitted to liquidliquid extraction using absolute chloroform (CHCl 3 ). The organic phase was separated and the solvent was evaporated, resulting in fraction 1 (F1). Next, ammonium hydroxide was added to the aqueous phase to increase the pH to the range 9-10 and this solution was then resubmitted to extraction with CHCl 3 . The organic phase was separated and the organic solvent evaporated, resulting in fraction 2 (F2). The remaining aqueous fraction was named F3. To identify the active compounds and to check the grade of purity, these three fractions were analyzed with thin-layer chromatography in silica using CHCl 3 Isolated compounds were checked for grade of purity using nuclear magnetic resonance (Varian Inc., USA) with scans at 500 MHz and tetramethylsilate as internal marker and deuterated chloroform (CD-CHCl 3 ) as solvent.
Surgery
Stainless-steel guide cannulas (0.7 × 10 mm) were implanted in animals (n = 6-8, each group) on anesthesia with ketamine and xylazine (60 and 8 mg/kg, ip, respectively). Animals were placed in a stereotaxic device (Stoelting-Standard, USA) and received a local injection of 2% lidocaine to expose the calvaria and place the guide cannula in the right lateral ventricle. The coordinates used were 0.9 mm posterior to bregma, 1.6 mm lateral from midline, and 3.4 mm ventral from the surface of the skull according to Paxinos and Watson [19] . The cannula was fixed to the skull using dental acrylate and was sealed with a stainless-steel wire to avoid obstruction. After the surgery, animals received an injection of Flunixin meglumine antiinflammatory (1.1 mg/kp, im). The animals were then allowed to rest for 5-7 days to recover from surgery.
Anticonvulsant screening
On the day of the experiments, with the aid of a digital infusion pump (Insight, Brazil) connected to a Hamilton syringe (10 μL) and an injection cannula, each animal was microinjected intracerebroventricularly (icv) with saline or each of the alkaloids in concentrations ranging from 0.25 to 3 μg/μL. Animals used as a positive control received diazepam (2 mg/kg, ip). After 10 minutes, chemoconvulsants were injected in doses adjusted to induce seizures in 97% of animals (CD 97 ), as follows: bicuculline (0.9 μg/μL, icv), NMDA (17 μg/μL, icv), kainic acid (0.8 μg/μL, icv), and PTZ (80 mg/kg, ip). Intracerebroventricular injections were administered in a total volume of 1 μL over 1 minute, whereas intraperitoneal injections were delivered in a volume of 0.3 mL.
Animals were observed for 30 minutes for the occurrence of seizures, and latency to onset or death was recorded. Seizures were classified using the limbic seizure scale [20] as follows: 0 = no seizure; 1 = orofacial movements; 2 = head myoclonus; 3 = hindlimb myoclonus; 4 = elevation; 5 = elevation and limbic fall; 6 = head and ear myoclonus; 7 = rotation, jumps, and vocalization; 8 = class 7 behaviors and hypertonus.
One day after the assays, animals were euthanized with an overdose of thiopental (100 mg/kg, ip; Cristalia, Brazil) and then injected with toluidine blue (1 μL, icv). Brains were removed, frozen, and manually cut to check placement of the cannula. Animals in which there was inaccurate placement (≅5%) were not considered in the analysis.
Data analysis
Number of animals protected against generalized chemically induced tonic-clonic seizures was plotted in relation to each concentration of the alkaloids used. These frequencies were then compared using the χ 2 test. Latency to seizure onset in animals not fully protected by the alkaloids was analyzed using one-way analysis of variance (ANOVA), followed by the Tukey post test. A P value b 0.05 was considered statistically significant. Data were analyzed and fitted using the software Graph Prism (Version 4.0, GraphPad Software, USA).
Results
Isolation and identification of alkaloids
Alkaloid purification was effective in providing the appropriate amount of alkaloids to perform bioassays. In this regard, we obtained 15.2 and 2.4 mg of (+)-11-α-hydroxy-erythravine and (+)-erythravine, respectively. The degree of purity for both alkaloids was confirmed by NMR spectra (see Appendix-Supplementary Material).
Anticonvulsant screening
Data from anticonvulsant screening of (+)-erythravine for protecting animals against seizures are summarized in Fig. 1 . The data indicate that intracerebroventricular microinjection of (+)-erythravine into rats prior to the administration of bicuculline inhibited seizures in 40, 60, and 80% of animals at doses of 1, 2, and 3 μg/μL, respectively (χ 2 [3] = 10.40, P = 0.015) (Fig. 1A) . In the NMDA assay, treatment with (+)-erythravine at 3 μg/μL (icv) blocked seizures in only 20% of animals (χ 2 [3] = 3.158, P = 0.3679) (Fig. 1B) . Systemic administration of PTZ (80 mg/kg, ip) induced generalized seizures in all injected animals, which were blocked by preadministration of (+)-erythravine in 60 and 100% of animals at doses of 1 and 2 or 3 μg/μL, respectively (χ 2 [3] = 14.73, P = 0.0021) (Fig. 1C) . In the kainic acid assay, pretreatment of animals with (+)-erythravine inhibited seizures in 40 and 100% of animals at doses of 1 and 2 or 3 μg/μL, respectively (χ 2 [4] = 20.19, P = 0.0005); 0.5 μg/μL was not protective (Fig. 1D) . The anticonvulsant activity of (+)-erythravine exhibited a dose-dependent profile in all experiments.
Data from anticonvulsant screening of (+)-11-α-erythravine for protecting animals against seizures are illustrated in Fig. 2 . Our results show that this alkaloid, when centrally applied to rats prior to the administration of bicuculline, inhibited seizures in all animals at 1 and 2 μg/μL, and inhibited seizures in 60% of animals at 0. (+)-11-α-hydroxyerythravine in 80% of animals at 0.5 μg/μL, whereas 100% of animals were protected from those seizures by the administration of 1 and 2 μg/μL (+)-11-α-hydroxy-erythravine (χ 2 [4] = 21.75, P = 0.0002) (Fig. 2B) . Seizures induced by systemic administration of PTZ were blocked by the pre-administration of (+)-11-α-hydroxy-erythravine in only 40 and 60% of animals at 2 and 3 μg/μL, respectively (χ 2 [3] = 7.200, P = 0.0658) (Fig. 2C ). In the case of kainic acid, 40 and 100% of animals were protected at 1 and 2 μg/μL, respectively (χ 2
[3] = 17.33, P = 0.0006) (Fig. 2D) . As observed for (+)-erythravine, the anticonvulsant activity of (+)-11-α-hydroxyerythravine exhibited a dose-dependent profile in all experiments.
In all experiments, microinjections of bicuculline (0.9 μg/μL, icv), NMDA (17 μg/μL, icv), PTZ (80 mg/kg, ip), and kainic acid (0.8 μg/μL, icv) induced tonic-clonic seizures in all animals pre-injected with saline. Conversely, diazepam protected 100% of animals against seizures.
Analysis of mean latency to seizure onset in unprotected animals for both alkaloids is summarized in Table 1 .
With respect to unprotected animals treated with (+)-erythravine, we observed an increase in latency to onset of seizures induced with bicuculline, although this increase was not statistically significant (F[2,12] = 3.486, P = 0.07). Analysis of animals treated with PTZ showed that at the only nonprotective dose (1 μg/μL), (+)-erythravine increased the mean latency to onset compared with that of animals injected with saline (t =9.014, P = 0.0008). Although (+)-erythravine showed very weak anticonvulsant activity against seizures induced with NMDA, in this assay, this alkaloid increased the latency to onset of seizures at doses of 2 and 3 μg/μL (F [3, 17] = 38.4, P b 0.0001). Administration of (+)-erythravine at 0.5 μg/μL before kainic acid decreased the latency to seizure onset as compared with that for animals injected with (+)-erythravine 1 μg/μL as well as saline, pointing to a proconvulsant effect at the lowest dose used (F [2, 17] = 38.4, P b 0.0001].
With respect to mean latency to seizure onset after treatment with (+)-11-α-hydroxy-erythravine, our findings showed that this alkaloid, at a dose of 0.5 μg/μL, increased the latency to onset of seizures evoked with bicuculline relative to the group injected with saline as well as the group injected with the lowest dose of the alkaloid (0.25 μg/μL) (F[2,14] = 55.46, P b 0.0001). The unprotected animals administered PTZ after (+)-11-α-hydroxy-erythravine exhibited seizures with heterogeneous latencies to seizure onset, and thus we did not observe statistical differences among means in these groups of animals (F [3, 13] increase the latency to seizure onset (t = 0.95, P = 0.37). However, administration of 0.5 μg/μL 11-α-hydroxy-erythravine induced a sevenfold increase in the latency to seizure onset of the only seizing animal. Regarding kainic acid-induced seizures, we observed a significant decrease in the latency to seizure onset in animals treated with (+)-11-α-hydroxy-erythravine 0.5 and 1 μg/μL (F[2,12]= 23.76, P b 0.0001). These findings are similar to those obtained for (+)-erythravine 0.5 μg/μL. All animals were protected against death when treated with different doses of (+)-11-α-hydroxy-erythravine before bicuculline, NMDA, PTZ, and kainic acid. Identical results were obtained when using (+)-erythravine in the tests of bicuculline, NMDA, and PTZ. However, the protection against death afforded by (+)-erythravine was 60, 80, and 100% at 0.5, 1, and 2 μg/μL (icv), respectively, in the kainic acid test. Mortality was 100% in animals injected only with saline before NMDA, PTZ, and kainic acid and 80% in animals injected only with saline before bicuculline.
Discussion
According to the World Health Organization (WHO), from 65 to 80% of the world's population, partially or totally, depends on nonconventional medicines for primary health care [21] . Plant extracts have been used in traditional folk medicine for centuries in the treatment of CNS disorders. With formalization of a pharmacological therapy approach, the pharmaceutical industry has tried to isolate and design neuroactive drugs from natural probes present in plants [22] .
In Brazilian traditional medicine, E. mulungu extracts are commonly used to treat anxiety and pain, as sedatives, and for blood pressure control [8, 10] . Scientific investigations have reported the neurobiological activity, including anticonvulsant, anxiolytic, and analgesic properties, of the hydroalcoholic extract of parts of E. mulungu [12] [13] [14] [15] [16] . The analgesic activity appears to be independent of opioid mechanisms [12] , and according to Vasconcelos and colleagues [16] , the hydroalcoholic extract of the stem bark from specimens of E. mulungu inhibits seizures induced in mice by the administration of strychnine and PTZ. Fractionation of E. mulungu extract revealed the presence of two major alkaloids: (+)-11-α-hydroxy-erythravine and (+)-erythravine. These alkaloids promote anxiolytic effects when administered to mice submitted to a light-dark choice apparatus and elevated plus maze [17, 18] .
Anxiety and epilepsy can be explained on the basis of similar neurobiological concepts, involving, in particular, alterations in the neurotransmitter balance in inhibitory and excitatory pathways. In fact, some anxiolytic drugs also act as anticonvulsants, such as the benzodiazepines. On the basis of the results presented, both anxiolytic alkaloids exhibited significant anticonvulsant activity against chemically induced seizures in rats. However, with respect to blocking generalized tonic-clonic seizures induced by two GABAergic antagonists, bicuculline and PTZ, and two glutamatergic agonists, NMDA and kainic acid, (+)-erythravine and (+)-11α-hydroxy-erythravine did not differ enough to predict a preferential action of these alkaloids on inhibitory or excitatory pathways. It has been suggested that alkaloids from Erythrina species act on the CNS by modifying GABA neurotransmission. It should be pointed out that agonists of GABA/benzodiazepine receptor typically promote motor impairment, particularly at higher doses [18, 23] . As suggested by Flausino and colleagues [18] , because the E. mulungu extract and (+)-erythravine/(+)-11-α-hydroxy-erythravine did not cause motor disruptions in mice [11] , it is reasonable to assume that these alkaloids could be not active only by a prevalent action on GABA neurotransmission. The characterization of the mode of action of these erythrinian alkaloids is currently underway in our laboratory.
Once again, as demonstrated by Vasconcelos and colleagues [11] , systemic administration of the E. mulungu hydroalcholic extract in doses up to 400 mg/kg does not impair motor coordination in female mice submitted to the rotarod test. Moreover, behavioral analysis of these animals in the open field pointed to a depressant effect on rearing and other parameters of exploratory behavior, which, according to the authors, could account for the sedative properties of the extract. We thus could consider the extract well tolerated. The importance of these data lies in the continuous need for novel and better tolerated antiepileptic drugs as therapy for the epilepsies as well as other syndromes of convulsive symptomatology [7] . As in the work of Flausino and colleagues [18] , the alkaloids (+)-erythravine and (+)-11-α-hydroxy-erythravine were orally administered to animals with resulting anxiolytic action; it is important to note that these alkaloids are well absorbed in the gastrointestinal tract and may be able to cross the blood-brain barrier, which is of relevance in the development of new drugs acting on the CNS, including antiepileptic drugs.
This work validates once more the ethnopharmacological potential of E. mulungu in the treatment of neurological disorders and also complies with biotechnological implications, as E. mulungu extract has been used in phytotherapeutic compositions/medicines in Brazil and the United States. In this context, continuing investigation of the mode of action of these alkaloids could lead to novel probes that could be used in rational drug design, as well as tools in the investigation of neural substrates that could be involved in the onset and maintenance of epileptic seizures.
